Thor Halfdanarson: The trial us CUP folks have been waiting for, CUPISCO

Thor Halfdanarson, Vice President at North American Neuroendocrine Tumor Society, shared a post on X

“The trial us CUP folks have been waiting for, CUPISCO

PFS better with molecularly-guided treatment but the difference is modest, 6.1 vs. 4.4 mos but better in the subgroup with actionable alterations.

Importantly, complex trials in rare cancers can be done, bravo”

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Authors: Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie Gj Robbrecht, Jiří Tomášek , Cagatay Arslan, Mustafa Özgüroğlu, Michael Stahl, Frédéric Bigot, Sun Young Kim, Yoichi Naito, Antoine Italiano, Nasséra Chalabi, Gonzalo Durán-Pacheco, Chantal Michaud, Jeremy Scarato, Marlene Thomas, Jeffrey S Ross , Holger Moch, and Linda Mileshkin .

Source: Thor Halfdanarson/X